IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Ranbaxy Buys 13 Drugs from BMS

7:04 AM MDT | August 6, 2007 | Chemical Week Editorial Staff

Ranbaxy Laboratories Inc. (RLI; Princeton, NJ), a wholly owned subsidiary of Ranbaxy Laboratories (Gurgaon, India), says it has acquired the U.S. rights to 13 dermatology products from Bristol-Myers Squibb (BMS). The U.S. dermatology market is valued at about $10 billion/year. The acquired brands have been in the market for more than a decade. They will be sold in the U.S. market under the RLI label. The deal “enables Ranbaxy to establish an immediate presence in the high-value segments of dermatitis, psoriasis, antifungals, and scabies, in addition to...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa